FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890372220> ?p ?o ?g. }

• W2890372220 endingPage "6432" @default.
• W2890372220 startingPage "6424" @default.
• W2890372220 abstract "Effective, programmatically suitable influenza vaccines are needed for low-resource countries. This phase II, placebo-controlled, randomized safety and immunogenicity trial (NCT01819155) was conducted in Senegal using the 2012–2013 Northern Hemisphere trivalent influenza vaccine (TIV) formulation. Participants were allocated in a 2:2:1 ratio to receive TIV (full-dose for all age groups), adjuvanted TIV (aTIV), or placebo. Participants were stratified into age groups: 6–11, 12–35, and 36–71 months. All participants were vaccine-naïve and received two doses of study vaccine 4 weeks apart. The two independent primary objectives were to estimate the immunogenicity of TIV and of aTIV as the proportion of children with a hemagglutination inhibition (HI) antibody titer of ≥1:40 to each vaccine strain at 28 days post-dose two. Safety was evaluated by solicited local and systemic reactions, unsolicited adverse events, and serious adverse events. 296 children received TIV, aTIV, or placebo, and 235 were included in the final analysis. After two doses, children aged 6–11, 12–35, and 36–71 months receiving TIV had HI titers ≥1:40 against A/H1N1 (73.1%, 94.1%, and 97.0%), A/H3N2 (96.2%, 100.0%, and 100.0%), and B (80.8%, 97.1%, and 97.0%), respectively. After two doses, 100% children aged 6–11, 12–35, and 36–71 months receiving aTIV had ≥1:40 titers against A/H1N1, A/H3N2, and B. After a single dose, the aTIV response was comparable to or greater than the TIV response for all vaccine strains. TIV and aTIV reactogenicity were similar, except for mild elevation in temperature (37.5–38.4 °C) which occurred more frequently in aTIV than TIV after each vaccine dose. TIV and aTIV had similarly increased pain/tenderness at the injection site compared to placebo. Both aTIV and full-dose TIV were well-tolerated and immunogenic in children aged 6–71 months. These vaccines may play a role in programmatically suitable strategies to prevent influenza in low-resource settings." @default.
• W2890372220 created "2018-09-27" @default.
• W2890372220 creator A5000435079 @default.
• W2890372220 creator A5001336078 @default.
• W2890372220 creator A5008909779 @default.
• W2890372220 creator A5021101907 @default.
• W2890372220 creator A5032741988 @default.
• W2890372220 creator A5038314998 @default.
• W2890372220 creator A5038539851 @default.
• W2890372220 creator A5040784545 @default.
• W2890372220 creator A5045971751 @default.
• W2890372220 creator A5051550648 @default.
• W2890372220 creator A5055592336 @default.
• W2890372220 creator A5068412542 @default.
• W2890372220 creator A5075218472 @default.
• W2890372220 creator A5083824687 @default.
• W2890372220 date "2018-10-01" @default.
• W2890372220 modified "2023-09-27" @default.
• W2890372220 title "Immunogenicity and safety of MF59-adjuvanted and full-dose unadjuvanted trivalent inactivated influenza vaccines among vaccine-naïve children in a randomized clinical trial in rural Senegal" @default.
• W2890372220 cites W1963590894 @default.
• W2890372220 cites W1983399734 @default.
• W2890372220 cites W2018262914 @default.
• W2890372220 cites W2028587022 @default.
• W2890372220 cites W2043687544 @default.
• W2890372220 cites W2075877458 @default.
• W2890372220 cites W2080860161 @default.
• W2890372220 cites W2099775797 @default.
• W2890372220 cites W2105225614 @default.
• W2890372220 cites W2111831969 @default.
• W2890372220 cites W2119450798 @default.
• W2890372220 cites W2135024896 @default.
• W2890372220 cites W2158639806 @default.
• W2890372220 cites W2172283179 @default.
• W2890372220 cites W2221137311 @default.
• W2890372220 cites W2236650526 @default.
• W2890372220 cites W2510979876 @default.
• W2890372220 cites W2530113419 @default.
• W2890372220 cites W2614986146 @default.
• W2890372220 cites W2739140450 @default.
• W2890372220 cites W2755826838 @default.
• W2890372220 cites W2756060030 @default.
• W2890372220 cites W2789260809 @default.
• W2890372220 cites W2795611591 @default.
• W2890372220 cites W4302076775 @default.
• W2890372220 doi "https://doi.org/10.1016/j.vaccine.2018.08.032" @default.
• W2890372220 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6327321" @default.
• W2890372220 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30224199" @default.
• W2890372220 hasPublicationYear "2018" @default.
• W2890372220 type Work @default.
• W2890372220 sameAs 2890372220 @default.
• W2890372220 citedByCount "11" @default.
• W2890372220 countsByYear W28903722202019 @default.
• W2890372220 countsByYear W28903722202020 @default.
• W2890372220 countsByYear W28903722202021 @default.
• W2890372220 countsByYear W28903722202023 @default.
• W2890372220 crossrefType "journal-article" @default.
• W2890372220 hasAuthorship W2890372220A5000435079 @default.
• W2890372220 hasAuthorship W2890372220A5001336078 @default.
• W2890372220 hasAuthorship W2890372220A5008909779 @default.
• W2890372220 hasAuthorship W2890372220A5021101907 @default.
• W2890372220 hasAuthorship W2890372220A5032741988 @default.
• W2890372220 hasAuthorship W2890372220A5038314998 @default.
• W2890372220 hasAuthorship W2890372220A5038539851 @default.
• W2890372220 hasAuthorship W2890372220A5040784545 @default.
• W2890372220 hasAuthorship W2890372220A5045971751 @default.
• W2890372220 hasAuthorship W2890372220A5051550648 @default.
• W2890372220 hasAuthorship W2890372220A5055592336 @default.
• W2890372220 hasAuthorship W2890372220A5068412542 @default.
• W2890372220 hasAuthorship W2890372220A5075218472 @default.
• W2890372220 hasAuthorship W2890372220A5083824687 @default.
• W2890372220 hasBestOaLocation W28903722202 @default.
• W2890372220 hasConcept C126322002 @default.
• W2890372220 hasConcept C142724271 @default.
• W2890372220 hasConcept C159654299 @default.
• W2890372220 hasConcept C168563851 @default.
• W2890372220 hasConcept C182072434 @default.
• W2890372220 hasConcept C197934379 @default.
• W2890372220 hasConcept C203014093 @default.
• W2890372220 hasConcept C204787440 @default.
• W2890372220 hasConcept C22070199 @default.
• W2890372220 hasConcept C27081682 @default.
• W2890372220 hasConcept C2776872762 @default.
• W2890372220 hasConcept C2777704310 @default.
• W2890372220 hasConcept C2780689484 @default.
• W2890372220 hasConcept C2780868878 @default.
• W2890372220 hasConcept C2909469553 @default.
• W2890372220 hasConcept C32611913 @default.
• W2890372220 hasConcept C71924100 @default.
• W2890372220 hasConceptScore W2890372220C126322002 @default.
• W2890372220 hasConceptScore W2890372220C142724271 @default.
• W2890372220 hasConceptScore W2890372220C159654299 @default.
• W2890372220 hasConceptScore W2890372220C168563851 @default.
• W2890372220 hasConceptScore W2890372220C182072434 @default.
• W2890372220 hasConceptScore W2890372220C197934379 @default.
• W2890372220 hasConceptScore W2890372220C203014093 @default.
• W2890372220 hasConceptScore W2890372220C204787440 @default.
• W2890372220 hasConceptScore W2890372220C22070199 @default.
• W2890372220 hasConceptScore W2890372220C27081682 @default.

• next